Atlas Genetics Enters Into Diagnostic Collaboration With a Major Pharmaceutical Company

Print 15 April 2015

First application of the Atlas io system outside of infectious diseases

Bath, UK, 15 April, 2015. Atlas Genetics Ltd (“Atlas Genetics” or the “Company”), the ultra-rapid ‘test and treat’ molecular diagnostics company, today announces that it has entered into a collaboration with a major pharmaceutical company to develop a diagnostic test, expanding capabilities beyond infectious diseases.

The io® system is a highly novel molecular diagnostic system developed initially for the ultra-rapid diagnosis of a broad range of infectious diseases.  It is based on a patent-protected electrochemical sensor technology that combines speed, accuracy and low manufacturing costs.  

The fully integrated cartridge contains all reagents on board and is designed to receive an unprocessed clinical specimen.  The cartridge is then inserted into the reader instrument which then completes the three-stage process of sample preparation, DNA amplification and electrochemical detection. Each cartridge can carry out up to 24 different tests from a single patient sample. This new companion diagnostic collaboration is the first outside of infectious disease.

Dr John Clarkson, Chief Executive Officer of Atlas Genetics, commented:  “We are delighted to be exploring this exciting new use of the io® system.  Our superior multiplexing capability allows for significant future menu expansion across a range of disease indications.  This new collaboration clearly demonstrates this flexibility and the wide ranging applicability of the Atlas Genetics io® system.” 

Notes to Editors

About Atlas Genetics (www.atlasgenetics.com)

Atlas Genetics develops ultra-rapid point-of-care (POC) diagnostic tests for infectious diseases. The Atlas Genetics io® system uses patented technology based on the use of a novel electrochemical sensor that combines speed, accuracy and multiplex detection capability.  The Company has its head office and laboratory facilities near Bath, UK.  Atlas Genetics was established in 2005 and is financed by VC, corporate and private investors including Novartis Venture Funds, Consort Medical plc, Johnson & Johnson Innovation - JJDC, Inc., LSP, BB Biotech Ventures, South West Ventures Fund and RMI Partners.

Return